- Home
- CTSO vs NVNO Comparison
CTSO vs NVNO Comparison
Compare CTSO & NVNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTSO
- NVNO
- Stock Information
- Founded
- CTSO 1997
- NVNO 1987
- Country
- CTSO United States
- NVNO United States
- Employees
- CTSO N/A
- NVNO N/A
- Industry
- CTSO Medical/Dental Instruments
- NVNO Medical/Dental Instruments
- Sector
- CTSO Health Care
- NVNO Health Care
- Exchange
- CTSO Nasdaq
- NVNO Nasdaq
- Market Cap
- CTSO 51.6M
- NVNO 61.9M
- IPO Year
- CTSO N/A
- NVNO N/A
- Fundamental
- Price
- CTSO $1.08
- NVNO $2.78
- Analyst Decision
- CTSO Strong Buy
- NVNO
- Analyst Count
- CTSO 3
- NVNO 0
- Target Price
- CTSO $4.67
- NVNO N/A
- AVG Volume (30 Days)
- CTSO 159.7K
- NVNO 109.6K
- Earning Date
- CTSO 05-08-2025
- NVNO 05-07-2025
- Dividend Yield
- CTSO N/A
- NVNO N/A
- EPS Growth
- CTSO N/A
- NVNO N/A
- EPS
- CTSO N/A
- NVNO N/A
- Revenue
- CTSO $37,739,531.00
- NVNO N/A
- Revenue This Year
- CTSO $9.20
- NVNO N/A
- Revenue Next Year
- CTSO $11.64
- NVNO $409.09
- P/E Ratio
- CTSO N/A
- NVNO N/A
- Revenue Growth
- CTSO 1.80
- NVNO N/A
- 52 Week Low
- CTSO $0.70
- NVNO $2.45
- 52 Week High
- CTSO $1.61
- NVNO $6.50
- Technical
- Relative Strength Index (RSI)
- CTSO 45.16
- NVNO 41.66
- Support Level
- CTSO $0.99
- NVNO $2.65
- Resistance Level
- CTSO $1.15
- NVNO $3.36
- Average True Range (ATR)
- CTSO 0.08
- NVNO 0.32
- MACD
- CTSO -0.02
- NVNO -0.07
- Stochastic Oscillator
- CTSO 10.53
- NVNO 24.59
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.
About NVNO enVVeno Medical Corporation
enVVeno Medical Corp is a medical device company focused on the development of bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. Its product, the VenoValve, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI).